DadFinStart your free week
DadFin › Stocks › Healthcare › VRTX

Vertex Pharmaceuticals Incorporate (VRTX) stock score

Healthcare · Biotechnology · United States

$510.08 ▲ +1.36% today

51.2
Dad Score, out of 100
middling

Vertex Pharmaceuticals Incorporate (VRTX) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 51.2 out of 100 on the Dad Score, a middling reading that places the business ahead of 51% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #402 of 974. Its strongest axes are quality, risk and liquidity; its weakest are valuation and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Strong
Growth
Average
Price action
Below average
Risk
Strong
Conviction
Average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)29.4×
P/E (forward)25.1×
Dividend yield0.00%
Return on capital21.4%
Operating margin38.0%
Revenue growth (YoY)+8.9%
FCF yield2.6%
Net debt / EBITDA-1.15×
Piotroski F-Score6 / 9
52-week change+25.3%
Market cap$127.8B
Next earningsNov 2, 2026

What subscribers see on VRTX

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
MRNAModerna, Inc.23.4weak$75.9B
REGNRegeneron Pharmaceuticals, Inc.91.1strong$75.7B
ARGXargenx SE55.1middling$57.5B
RVMDRevolution Medicines, Inc.40.6middling$44.3B
ONCBeOne Medicines AG94.5strong$40.7B
RPRXRoyalty Pharma plc70.8good$33.0B
ALNYAlnylam Pharmaceuticals, Inc.83.8good$29.4B
ROIVRoivant Sciences Ltd.19.5weak$25.8B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.